Search results
Jun 25, 2024 · Biocon Biologics, a global biosimilars company and a subsidiary of Biocon Ltd has received approval from European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab, a type of targeted ...
Jun 24, 2024 · Biocon Biologics is an international fully integrated biosimilar subsidiary of listed Biocon Limited. Biocon Biologics offers a portfolio of eight commercialised biosimilars across the globe which include Insulin Glargine, Insulin Aspart, recombinant Human Insulin, Trastuzumab, Bevacizumab, Pegfilgrastim, Adalimumab and Etanercept. The company expects to include 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. ...
Mar 14, 2024 · Biocon Biologics Limited, a fully integrated global biosimilars company and a subsidiary of Biocon Limited (BSE code: 532523, NSE: BIOCON), today announced a long -term commercial collaboration with Eris Lifesciences to expand patient access to its portfolio of Metabolics, Oncology, and Critical Care products in India.
Biocon Biologics Ltd on Monday announced that it has received approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab at its new multi-product monoclonal antibodies ...
Transforming Healthcare. Transforming Lives. | Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge ...
Jun 24, 2024 · The approval of Yesafili marked Biocon Biologics' entry into the ophthalmology therapeutic domain in the United States. This follows a consistent track record of approvals for Yesafili in Europe (September 2023) and the United Kingdom (November 2023), where it was the first biosimilar aflibercept to gain approval. Also Read: Hero MotoCorp to hike rates of certain motorcyles, scooters from July 1, 2024.
Sep 6, 2023 · Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the Company has completed the integration of the acquired biosimilars business...
Rhonda Duffy is the Chief Operating Officer at Biocon Biologics and is responsible for leading our global operations functions, Manufacturing, MSAT, Quality, Supply Chain Management (SCM) and Projects.
May 28, 2023 · Biocon Biologics Ltd (BBL) has ended financial year 2023 (FY23) on a high. The year marks an inflection point in its value creation journey as the acquisition of partner Viatris’ biosimilars business has catapulted the company into the global big league.
Jun 24, 2024 · Bengaluru: Biocon Biologics, a subsidiary of Biocon, on Monday got approval from the European Medicines Agency (EMA) to manufacture biosimilar Bevacizumab in India. The company, in a statement, said the biosimilar Bevacizumab will be manufactured at its new multi-product monoclonal antibodies (mAbs) drug substance facility in Bengaluru.
